Sign in
CompletedPhase 2

Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes

Key facts

Who runs it
Lin Chen
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
150 people enrolled
Started
1 Jan 2021
Ended
31 Dec 2023
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • esmolol
Record updated
29 May 2024

Who can take part

Age
18 years to 90 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (13)Hide the full registry criteria

Who can take part

  • Patients aged between 18 and 90 years
  • Diagnosed with sepsis or septic shock according to the diagnostic criteria in Suivival Sepsis of 2021
  • Received adequate fluid resuscitation and necessary exogenous Norepinephrine (NE)
  • No contraindications to Esmolol and appropriate heart rate levels determined by clinical assessment
  • Provided written informed consent

Who cannot take part

  • Underwent surgical procedures within the last two weeks
  • Received high doses of corticosteroids in the past three months
  • Underwent significant hormone therapy, persistent blood loss of more than 500 ml within any 24-hour period, or were treated with Esmolol for less than three days
  • Severe cardiac failure exceeding NYHA Class III
  • Deceased within three days following ICU admission
  • Pregnant or lactating individuals
  • Usage of long-term oral β-blockers or any form of extracorporeal circulation within the last two weeks
  • Presenting with sinus bradycardia or atrioventricular block

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Evaluate the effectiveness of esmolol, a selective β1-adrenergic receptor blocker, in modulating immune responses and improving patient outcomes in sepsis.

The 2 groups in the trial

  • standard care plus esmololTreatment being tested

    Patients in this group were administered Esmolol, a beta-1 selective adrenergic blocker, alongside the standard sepsis care protocols. The dosage of Esmolol was adjusted to maintain heart rate within predefined targets. Additionally, daily electrocardiogram (ECG) monitoring was conducted to assess changes in the QT interval, a critical measure given the potential cardiac effects of beta-blockers. This group aimed to explore not only the immunomodulatory effects of Esmolol but also its safety profile in terms of cardiac function in septic patients.

    Treatment: esmolol

  • standard careNo study treatment, for comparison

    Patients in this cohort received the standard of care for sepsis without any additional intervention. This treatment included antibiotics, fluids, and other supportive therapies as dictated by current clinical guidelines for sepsis management.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Investigating the Immunomodulatory Effects of Esmolol in Sepsis Management and Its Impact on Patient Outcomes
Publications
Record updated
29 May 2024